Патогенез ВИЧ-инфекции: 25 лет открытий и загадок ... - Tb-hiv.ru

Èñ÷åçíîâåíèå ÐÍÊ HCV èç ïëàçìû êðîâè ÷åðåç 4 íåä. òåðàïèè êàê ïðåäèêòîð ÓÂÎ14122. Alberti A, Clumeck N, Collins S, et al. Short Statement of the First EuropeanConsensus Conference on the treatment of chronic hepatitisB and C in HIV co-infected patients. J Hepatol 2005; 42:615–624.23. Cargnel A, Angeli E, Mainini A, et al. Open, randomized, multicentreItalian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapyfor chronic hepatitis C in HIV-coinfected patients on HAART. AntivirTher 2005; 10:309–317.24. Nunez M, Miralles C, Berdun MA, et al. Role of weight-based ribavirindosing and extended duration of therapy in the treatment ofchronic hepatitis C in HIV-infected patients: the PRESCO Trial. AIDSRes Human Retroviruses 2007; 23:972–982.25. Soriano V, Miralles C, Berdun MA, et al. Frequency and causes ofpremature treatment discontinuation in HIV/HCV-coinfected patientsreceiving pegylated interferon alpha-2a plus weight-basedribavirin. Antivir Ther, 2007; In press.26. Zeuzem S. Heterogeneous virologic response rates to interferonbasedtherapy in patients with chronic hepatitis C: who respondsless well? Ann Intern Med 2004; 140:370–381.27. Soriano V, Puoti M, Sulkowski M, et al. Care of patients coinfectedwith HIV and hepatitis C virus: 2007 updated recommendationsfrom the HCV-HIV International Panel. AIDS 2007; 21:1073–1089.28. Sherman K, Shire N, Rouster S, et al. Viral kinetics in hepatitis C orhepatitis C/HIV-infected patients. Gastroenterology 2005; 128:313–327.29. Martinez-Bauer E, Crespo J, Romero-Gomez M, et al. Developmentand validation of two models for early prediction of response to therapyin genotype 1 chronic hepatitis C. Hepatology 2006; 43:72–80.30. Crespo M, Esteban JI, Ribera E, et al. Utility of week-4 viral responseto tailor treatment duration in hepatitis C virus genotype 3/HIV coinfectedpatients. AIDS 2007; 21:477–481.31. Hopkins S, Lambourne J, Farrell G, et al. Role of individualization ofHCV therapy duration in HIV/HCV-coinfected individuals. HIV Med2006; 7:248–254.32. Zeuzem S, Fried M, Reddy K, et al. Improving the clinical relevanceof pretreatment viral load as a predictor of sustained virological responsein patients infected with hepatitis C genotype 1 treated withpeginterferon alfa-2a plus ribavirin. In: 57th Annual Meeting of theAmerican Association for the Study of Liver Diseases. Boston, MA;27–31 October 2006; Abstract 209.33. Berg T, Von Wagner M, Hinrichsen H, et al. Definition of a pretreatmentviral load cut-off for an optimized prediction of treatmentoutcome in patients with genotype 1 infection receiving either 48or 72 weeks of peginterferon alfa-2a plus ribavirin. In: 57th AnnualMeeting of the American Association for the Study of Liver Diseases.Boston, MA; 27–31 October 2006; Abstract 350.34. Soriano V, Barreiro P, Nunez M. Management of chronic hepatitisB and C in HIV-coinfected patients. J Antimicrob Chemother 2006;57:815–818.35. Sanchez-Tapias J, Diago M, Escartin P, et al. Peginterferon-alfa 2aplus ribavirin for 48 versus 72 weeks in patients with detectable hepatitisC virus RNA at week 4 of treatment. Gastroenterology 2006;131:451–460.36. Berg T, Von Wagner M, Nasser S, et al. Extended treatment durationfor hepatitis C virus type 1: comparing 48 versus 72 weeksof peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006;130:1086–1097.37. Uriel A, Moorehead L, Carriero D, Sulkowski M, Dieterich D. TheHepatitis Resource Network Clinical Trials Group. A multicenter,randomized trial of 48 vs 72 weeks of peg-interferon-2b + ribavirinin HIV/HCV co-infected subjects: longer therapy does not correlatewith improved sustained virological response. In: 13th Conferenceon Retroviruses and Opportunistic Infections. Denver, CO; 5–8 February2006; Abstract 854.38. Fontana R. Optimizing outcomes in hepatitis C: is treatment beyond48 weeks ever justified? Gastroenterology 2006; 130:1357–1362.